Immunologix, Inc, a Charleston, SC biotechnology company and a leader in fully human therapeutic antibodies for a variety of diseases and GenScript, a contract research organization (CRO) based in Piscataway, NJ and the industry leader in bio‐reagent services, assay development & screening, lead optimization, and antibody drug development, announced today that the companies have formed a strategic partnership to offer a complete platform for producing human antibody therapeutics. Immunologix holds the exclusive worldwide license rights to a proprietary technique used to produce fully human antibodies.
GenScript offers extensive antibody drug services that include antigen production, hybridoma development and stabilization, antibody sequencing, chimeric antibody, antibody humanization, affinity maturation, epitope mapping, antibody and protein characterization, in vitro assay and screening, in vivo efficacy and safety study, antibody transient expression, stable cell line, and scale up production. Jointly, the companies provide an integrated platform for discovery and development of full human therapeutic antibody candidates ready for clinical trials.
“This relationship between Immunologix and GenScript has been building since initial discussions began in July 2010. GenScript is one of the global leaders in antibody drug development with resources and expertise. Having this partnership allows both parties to offer their clients a 100% fully human monoclonal antibody ready for clinical trials. We couldn’t think of a better company to partner with for this part of our product development” said Dr. Ryan Fiorini, Founder and Chief Operating Officer of Immunologix. “This agreement is a win‐win for both companies and we are happy to team up with GenScript to expand our capability and capacity.”
“GenScript is pleased to form the strategic alliance with Immunologix, a world leader in human antibody therapeutics by novel approach. The partnership provides GenScript the access to Immunologix’ proprietary technology and complements its antibody drug development service platform.” commented Dr. Nick Yan, Vice President of GenScript. “Jointly, we can offer one‐stop solutions and complete portfolios to our clients for all their needs in human therapeutic antibody from target identification to clinic candidates cost‐effectively and time‐efficiently”.
Immunologix, Inc., is a human antibody discovery and development company specializing in transforming naïve B‐cells to produce fully human antibodies that can target any and all antigens including cancer, viruses, bacteria, toxins and auto‐immune diseases like diabetes, lupus, rheumatoid
arthritis and multiple sclerosis to name a few. More specific information about the Immunologix process can be found on their website at www.ImmunoLogix.com
Immunologix collects patient consented explanted tonsil tissue following a tonsillectomy from patients in the Charleston, SC area. Immunologix captures billions of cells from each tonsil and processes them in its state of the art laboratory at the new SCRA Innovation Center at 645 Meeting Street in Charleston, SC.
GenScript, is a CRO specialized in biological research and drug discovery services. Its service portfolio includes bio‐reagent services, assay development & screening, lead optimization, and antibody drug development. The renowned one‐stop bio‐reagent services include custom gene synthesis and molecular biology, custom protein expression and purification, custom peptide synthesis, antibody production, and custom cell line development. Headquartered in Piscataway, New Jersey, GenScript has become a world‐leading Biology CRO and the largest gene synthesis supplier in the USA, with subsidiaries in France, Japan, and China. Recently, the company received $15M investment led by Kleiner Perkins Caufield & Byers (KPCB) to expand its biology and bio‐reagent services in drug discovery and development. www.GenScript.com